ATE199553T1 - Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung - Google Patents

Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung

Info

Publication number: ATE199553T1
Authority: AT; Austria
Prior art keywords: compounds; alkyl; pct; trifluoromethyl; unsubstituted
Prior art date: 1994-09-29

Application number

AT95932693T

Other languages

English (en)

Inventor

Martin Missbach

Original Assignee

Novartis Erfind Verwalt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-29

Filing date

1995-09-08

Publication date

2001-03-15

1995-09-08 Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh

2001-03-15 Application granted granted Critical

2001-03-15 Publication of ATE199553T1 publication Critical patent/ATE199553T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

AT95932693T 1994-09-29 1995-09-08 Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung ATE199553T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH295394		1994-09-29
PCT/EP1995/003536 WO1996010028A1 (en)	1994-09-29	1995-09-08	PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE

Publications (1)

Publication Number	Publication Date
ATE199553T1 true ATE199553T1 (de)	2001-03-15

Family

ID=4245363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95932693T ATE199553T1 (de)	1994-09-29	1995-09-08	Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung

Country Status (20)

Country	Link
US (1)	US5869485A (de)
EP (1)	EP0783505B1 (de)
JP (1)	JP4145955B2 (de)
KR (1)	KR970706288A (de)
CN (1)	CN1046731C (de)
AT (1)	ATE199553T1 (de)
AU (1)	AU694801B2 (de)
BR (1)	BR9509048A (de)
CA (1)	CA2200210A1 (de)
DE (1)	DE69520282T2 (de)
DK (1)	DK0783505T3 (de)
ES (1)	ES2157344T3 (de)
FI (1)	FI112867B (de)
GR (1)	GR3035996T3 (de)
HU (1)	HU222181B1 (de)
MX (1)	MX9702307A (de)
NO (1)	NO308108B1 (de)
NZ (1)	NZ293249A (de)
PT (1)	PT783505E (de)
WO (1)	WO1996010028A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0682027T3 (da) *	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
MX9800215A (es) *	1995-07-06	1998-03-31	Novartis Ag	Pirrolopirimidas y procesos para su preparacion.
AU3176297A (en) *	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EP0912562A1 (de) *	1996-07-19	1999-05-06	Takeda Chemical Industries, Ltd.	Heterocyclische verbindungen, ihre herstellung und verwendung
JP4056589B2 (ja) *	1996-07-19	2008-03-05	武田薬品工業株式会社	複素環化合物、その製造法および用途
ATE384062T1 (de)	1996-08-23	2008-02-15	Novartis Pharma Gmbh	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
WO1998014450A1 (en)	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en)	1997-03-11	1997-04-30	Knoll Ag	Therapeutic agents
ID24653A (id) *	1997-03-19	2000-07-27	Basf Ag	Zat-zat terapi
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
JP3711238B2 (ja) *	1997-08-05	2005-11-02	ファイザー・プロダクツ・インク	神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
MXPA00011889A (es) *	1998-06-02	2003-04-25	Osi Pharm Inc	Composiciones de pirrolo (2,3d) piridina y su uso.
JP2002526500A (ja) *	1998-09-18	2002-08-20	ビーエーエスエフアクチェンゲゼルシャフト	プロテインキナーゼ阻害剤としてのピロロピリミジン
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
SK3812002A3 (en)	1999-09-17	2003-09-11	Abbott Gmbh & Co Kg	Pyrazolopyrimidines as therapeutic agents
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2005502643A (ja) *	2001-08-10	2005-01-27	ノバルティス　アクチエンゲゼルシャフト	白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
US6770652B2 (en) *	2001-10-18	2004-08-03	Duquesne University Of The Holy Ghost	Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) *	2001-12-24	2003-07-03	Merck Patent Gmbh	Pyrrolo-pyrimidine
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
GB0226370D0 (en) *	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
US7157460B2 (en) *	2003-02-20	2007-01-02	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
JP2007520559A (ja) *	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
EP2385053B1 (de) *	2005-11-17	2013-10-02	OSI Pharmaceuticals, Inc.	Zwischenprodukte für die Herstellung von kondensierten bicyclischen mTOR-Inhibitoren
ES2545907T3 (es) *	2005-12-29	2015-09-16	Abbvie Inc.	Inhibidores de proteína quinasa
EP1981890A2 (de) *	2006-01-25	2008-10-22	OSI Pharmaceuticals, Inc.	UNGESÄTTIGTE mTOR-HEMMER
KR20110017845A (ko) *	2008-03-19	2011-02-22	오에스아이 파마슈티컬스, 인코포레이티드	Ｍｔｏｒ 억제자 염 형태
ES2570429T3 (es) *	2008-10-16	2016-05-18	Univ California	Inhibidores de heteroaril quinasa de anillo condensado
WO2010066629A2 (en) *	2008-12-09	2010-06-17	F. Hoffmann-La Roche Ag	Novel azaindoles
BR112012005400A2 (pt)	2009-09-10	2016-04-05	Irm Llc	derivados do tipo éter de heteroarilas bicíclicas
JP2013512215A (ja)	2009-11-25	2013-04-11	ノバルティスアーゲー	二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
JP2013532149A (ja)	2010-06-17	2013-08-15	ノバルティスアーゲー	ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN102947274A (zh)	2010-06-17	2013-02-27	诺瓦提斯公司	联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2014507465A (ja)	2011-03-08	2014-03-27	ノバルティスアーゲー	フルオロフェニル二環式ヘテロアリール化合物
AU2012225232B2 (en)	2011-03-09	2016-05-12	Richard G. Pestell	Prostate cancer cell lines, gene signatures and uses thereof
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2873743C (en)	2012-05-14	2022-12-06	Prostagene, Llc	Using modulators of ccr5 for treating cancer
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3194572B1 (de)	2014-07-30	2023-10-25	Yeda Research and Development Co. Ltd.	Medien zur kultivierung pluripotenter stammzellen
WO2017027883A1 (en)	2015-08-13	2017-02-16	San Diego State University Research Foundation	Atropisomerism for increased kinase inhibitor selectivity
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
EP3730483B1 (de)	2017-12-21	2023-08-30	Hefei Institutes of Physical Science, Chinese Academy of Sciences	Klasse von pyrimidinderivaten als kinaseinhibitoren
WO2020113094A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
WO2020152686A1 (en)	2019-01-23	2020-07-30	Yeda Research And Development Co. Ltd.	Culture media for pluripotent stem cells
WO2021097256A1 (en)	2019-11-14	2021-05-20	Cohbar, Inc.	Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) *	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning

1995
- 1995-09-08 WO PCT/EP1995/003536 patent/WO1996010028A1/en active IP Right Grant
- 1995-09-08 US US08/793,313 patent/US5869485A/en not_active Expired - Lifetime
- 1995-09-08 PT PT95932693T patent/PT783505E/pt unknown
- 1995-09-08 AT AT95932693T patent/ATE199553T1/de not_active IP Right Cessation
- 1995-09-08 DK DK95932693T patent/DK0783505T3/da active
- 1995-09-08 AU AU35643/95A patent/AU694801B2/en not_active Ceased
- 1995-09-08 KR KR1019970702044A patent/KR970706288A/ko active IP Right Grant
- 1995-09-08 MX MX9702307A patent/MX9702307A/es not_active IP Right Cessation
- 1995-09-08 NZ NZ293249A patent/NZ293249A/en active IP Right Revival
- 1995-09-08 CA CA002200210A patent/CA2200210A1/en not_active Abandoned
- 1995-09-08 DE DE69520282T patent/DE69520282T2/de not_active Expired - Lifetime
- 1995-09-08 EP EP95932693A patent/EP0783505B1/de not_active Expired - Lifetime
- 1995-09-08 CN CN95196308A patent/CN1046731C/zh not_active Expired - Fee Related
- 1995-09-08 ES ES95932693T patent/ES2157344T3/es not_active Expired - Lifetime
- 1995-09-08 JP JP51131296A patent/JP4145955B2/ja not_active Expired - Fee Related
- 1995-09-08 HU HU9701333A patent/HU222181B1/hu not_active IP Right Cessation
- 1995-09-08 BR BR9509048A patent/BR9509048A/pt not_active IP Right Cessation
1997
- 1997-03-21 NO NO971342A patent/NO308108B1/no not_active IP Right Cessation
- 1997-03-24 FI FI971225A patent/FI112867B/fi active
2001
- 2001-06-06 GR GR20010400849T patent/GR3035996T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1046731C (zh)	1999-11-24
NO971342L (no)	1997-03-21
HU222181B1 (hu)	2003-04-28
DE69520282T2 (de)	2001-08-09
NO308108B1 (no)	2000-07-24
AU3564395A (en)	1996-04-19
JPH10506624A (ja)	1998-06-30
FI112867B (fi)	2004-01-30
FI971225A (fi)	1997-05-14
EP0783505B1 (de)	2001-03-07
HUT76785A (en)	1997-11-28
DK0783505T3 (da)	2001-07-02
DE69520282D1 (de)	2001-04-12
NZ293249A (en)	1999-04-29
ES2157344T3 (es)	2001-08-16
CA2200210A1 (en)	1996-04-04
US5869485A (en)	1999-02-09
AU694801B2 (en)	1998-07-30
JP4145955B2 (ja)	2008-09-03
MX9702307A (es)	1998-04-30
CN1164234A (zh)	1997-11-05
FI971225A0 (fi)	1997-03-24
KR970706288A (ko)	1997-11-03
NO971342D0 (no)	1997-03-21
PT783505E (pt)	2001-08-30
WO1996010028A1 (en)	1996-04-04
BR9509048A (pt)	1998-01-06
EP0783505A1 (de)	1997-07-16
GR3035996T3 (en)	2001-09-28

Legal Events

Date	Code	Title	Description
2001-08-15	UEP	Publication of translation of european patent specification
2011-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE199553T1 (de)	2001-03-15	Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung
AP2002002643A0 (en)	2002-12-31	5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CY1105618T1 (el)	2010-12-22	Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
EA200200473A1 (ru)	2002-10-31	Ингибиторы тирозинкиназы
CY1107509T1 (el)	2013-03-13	Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
MY134848A (en)	2007-12-31	Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
ES2193362T3 (es)	2003-11-01	Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos.
DK0938486T3 (da)	2008-07-07	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
HUP0004807A2 (hu)	2001-11-28	Vérlemezkéből származó növekedési faktort és/vagy P56lck tirozin kinázokat gátló hatású kinolin- és kinoxalin-vegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
AR006906A1 (es)	1999-09-29	Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
ATE301116T1 (de)	2005-08-15	Aminopyrazol derivate
DE69709624D1 (de)	2002-02-21	Chinazolinverbindungen
EA200000842A1 (ru)	2001-04-23	Бицикло [2.2.1] гептаны и родственные соединения
PT880507E (pt)	2005-07-29	Derivados de quinazolina como agentes anti-tumorais
TR199900048T2 (xx)	1999-04-21	Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
EA199900022A1 (ru)	1999-08-26	Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
DE69739733D1 (de)	2010-02-25	1-phenyl-benzimidazolverbindungen und ihre verwendung als modulatoren des gaba-a-rezeptors
EA200400475A1 (ru)	2004-08-26	Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
UA87895C2 (en)	2009-08-25	Substituted 5-phenyl pyrimidines i in therapy
ATE150751T1 (de)	1997-04-15	Neuroprotektive 3,4-dihydro-2(1h)-chinolone
DK0526588T3 (da)	1994-08-22	Heterocykliske forbindelser, deres fremstilling og anvendelse
MXPA05010975A (es)	2005-11-28	Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
UY26866A1 (es)	2001-09-28	Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenilpirido (2,3-d) pirimidin-7-onas
ATE193705T1 (de)	2000-06-15	4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen- - on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie
ES2193047T3 (es)	2003-11-01	(3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.